Glycosaminoglycan mimetic improves enrichment and cell functions of human endothelial progenitor cell colonies

Stem Cell Research

Volumn 12, Issue 3, 2014, Pages 703-715

  Chevalier, Fabien ^a,b   Lavergne, Mélanie ^c   Negroni, Elisa ^b   Ferratge, Ségolène ^b   Carpentier, Gilles ^a   Gilbert Sirieix, Marie ^d   Siñeriz, Fernando ^d   Uzan, Georges ^b   Albanese, Patricia ^a  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c ABCell Bio SAS   (France)

^d OTR3 company ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN;

ANIMAL CELL; ARTICLE; CELL ADHESION; CELL CULTURE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL REGENERATION; CELL THERAPY; COLONY FORMING CELL; CONTROLLED STUDY; ENDOTHELIAL COLONY FORMING CELL; ENDOTHELIAL PROGENITOR CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; UMBILICAL CORD BLOOD; CELL MOTION; CFU COUNTING; CHEMISTRY; CYTOLOGY; FETUS BLOOD; MALE; METABOLISM; NEWBORN;

CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; ENDOTHELIAL PROGENITOR CELLS; FEMALE; FETAL BLOOD; GLYCOSAMINOGLYCANS; HUMANS; INFANT, NEWBORN; MALE;

EID: 84897105840     PISSN: 18735061     EISSN: 18767753     Source Type: Journal    
DOI: 10.1016/j.scr.2014.03.001     Document Type: Article

References (58)

1. Alaiti M.A., Ishikawa M., Costa M.A. Bone marrow and circulating stem/progenitor cells for regenerative cardiovascular therapy. Transl. Res. 2010, 156(3):112-129.
2. Albanese P., et al. Glycosaminoglycan mimetics-induced mobilization of hematopoietic progenitors and stem cells into mouse peripheral blood: structure/function insights. Exp. Hematol. 2009, 37(9):1072-1083.
3. Asahara T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275(5302):964-967.
4. Ashikari-Hada S., et al. Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins. J. Biol. Chem. 2005, 280(36):31508-31515.
5. Au P., et al. Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. Blood 2008, 111(3):1302-1305.
6. Barritault D., Caruelle J.P. Regenerating agents (RGTAs): a new therapeutic approach. Ann. Pharm. Fr. 2006, 64(2):135-144.
7. Bompais H., et al. Human endothelial cells derived from circulating progenitors display specific functional properties compared with mature vessel wall endothelial cells. Blood 2004, 103(7):2577-2584.
8. Carpentier G. Angiogenesis analyzer for ImageJ http://rsb.info.nih.gov/ij/macros/toolsets/Angiogenesis%20Analyzer.txt.
9. Carpentier G., et al. Angiogenesis analyzer. 4th ImageJ User and Developer Conference Proceedings 2012, 198-201.
10. Cole C.L., et al. Synthetic heparan sulfate oligosaccharides inhibit endothelial cell functions essential for angiogenesis. PLoS One 2010, 5(7):e11644.
11. Cory A.H., et al. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 1991, 3(7):207-212.
12. Desgranges P., et al. A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle. Faseb J. 1999, 13(6):761-766.
13. Desgranges P., et al. Beneficial use of fibroblast growth factor 2 and RGTA, a new family of heparan mimics, for endothelialization of PET prostheses. J. Biomed. Mater. Res. 2001, 58(1):1-9.
14. Destouches D., et al. Multivalent pseudopeptides targeting cell surface nucleoproteins inhibit cancer cell invasion through tissue inhibitor of metalloproteinases 3 (TIMP-3) release. J. Biol. Chem. 2012, 287(52):43685-43693.
15. Frescaline G., et al. Glycosaminoglycans mimetics potentiate the clonogenicity, proliferation, migration and differentiation properties of rat mesenchymal stem cells. Stem Cell Res. 2011, 8(2):180-192.
16. Frescaline G., et al. Glycosaminoglycan mimetic associated to human mesenchymal stem cell based scaffolds inhibit ectopic bone formation but induce angiogenesis in vivo. Tissue Eng. Part A 2013, 19(13-14):1641-1653.
17. Friedl A., et al. Differential binding of fibroblast growth factor-2 and -7 to basement membrane heparan sulfate: comparison of normal and abnormal human tissues. Am. J. Pathol. 1997, 150(4):1443-1455.
18. Gallagher J.T. Multiprotein signalling complexes: regional assembly on heparan sulphate. Biochem. Soc. Trans. 2006, 34(Pt 3):438-441.
19. Gandhi N.S., Mancera R.L. The structure of glycosaminoglycans and their interactions with proteins. Chem. Biol. Drug Des. 2008, 72(6):455-482.
20. Gitay-Goren H., et al. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J. Biol. Chem. 1992, 267(9):6093-6098.
21. Goger B., et al. Different affinities of glycosaminoglycan oligosaccharides for monomeric and dimeric interleukin-8: a model for chemokine regulation at inflammatory sites. Biochemistry 2002, 41(5):1640-1646.
22. Handel T.M., et al. Regulation of protein function by glycosaminoglycans-as exemplified by chemokines. Annu. Rev. Biochem. 2005, 74:385-410.
23. Hristov M., et al. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ. Res. 2007, 100(4):590-597.
24. Huynh M.B., et al. Age-related changes in rat myocardium involve altered capacities of glycosaminoglycans to potentiate growth factor functions and heparan sulfate-altered sulfation. J. Biol. Chem. 2012, 287(14):11363-11373.
25. Huynh M.B., et al. Glycosaminoglycans from aged human hippocampus have altered capacities to regulate trophic factors activities but not Abeta42 peptide toxicity. Neurobiol. Aging 2012, 33(5):1005. e11-22.
26. Ingber D.E. Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. Circ. Res. 2002, 91(10):877-887.
27. Ingram D.A., et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004, 104(9):2752-2760.
28. Janic B., et al. Human cord blood-derived AC133+ progenitor cells preserve endothelial progenitor characteristics after long term in vitro expansion. PLoS One 2010, 5(2):e9173.
29. Kalka C., et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(7):3422-3427.
30. Khan S.S., Solomon M.A., McCoy J.P. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin. Cytom. 2005, 64(1):1-8.
31. Kraushaar D.C., Dalton S., Wang L. Heparan sulfate: a key regulator of embryonic stem cell fate. Biol. Chem. 2013, 394(6):741-751.
32. Lavergne M., et al. Porous polysaccharide-based scaffolds for human endothelial progenitor cells. Macromol. Biosci. 2012, 12(7):901-910.
33. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473(7347):317-325.
34. Lippross S., et al. Platelet released growth factors boost expansion of bone marrow derived CD34(+) and CD133(+) endothelial progenitor cells for autologous grafting. Platelets 2011, 22(6):422-432.
35. Meddahi A., et al. Pharmacological studies of RGTA(11), a heparan sulfate mimetic polymer, efficient on muscle regeneration. J. Biomed. Mater. Res. 2002, 62(4):525-531.
36. Murray C.J., Lopez A.D. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997, 349(9061):1269-1276.
37. O.E., et al. Efficient nonadhesive ex vivo expansion of early endothelial progenitor cells derived from CD34+ human cord blood fraction for effective therapeutic vascularization. Faseb J. 2011, 25(1):159-169.
38. Ono K., et al. Structural features in heparin that interact with VEGF165 and modulate its biological activity. Glycobiology 1999, 9(7):705-711.
39. Ouidja M.O., et al. Structure-activity studies of heparan mimetic polyanions for anti-prion therapies. Biochem. Biophys. Res. Commun. 2007, 363(1):95-100.
40. Papy-Garcia D., et al. Nondegradative sulfation of polysaccharides. Synthesis and structure characterization of biologically active heparan sulfate mimetics. Macromolecules 2005, 38:4647-4654.
41. Pettengell R., et al. Direct comparison by limiting dilution analysis of long-term culture-initiating cells in human bone marrow, umbilical cord blood, and blood stem cells. Blood 1994, 84(11):3653-3659.
42. Purushothaman A., Sugahara K., Faissner A. Chondroitin sulfate "wobble motifs" modulate maintenance and differentiation of neural stem cells and their progeny. J. Biol. Chem. 2012, 287(5):2935-2942.
43. Rasband W.S. ImageJ 1997-2013, U. S. National Institutes of Health, Bethesda, Maryland, USA, (http://rsb.info.nih.gov/ij/).
44. Rouet V., et al. A synthetic glycosaminoglycan mimetic binds vascular endothelial growth factor and modulates angiogenesis. J. Biol. Chem. 2005, 280(38):32792-32800.
45. Sasaki N., et al. Heparan sulfate regulates self-renewal and pluripotency of embryonic stem cells. J. Biol. Chem. 2008, 283(6):3594-3606.
46. Schenauer M.R., et al. CCR2 chemokines bind selectively to acetylated heparan sulfate octasaccharides. J. Biol. Chem. 2007, 282(35):25182-25188.
47. Schlechta B., et al. Ex-vivo expanded umbilical cord blood stem cells retain capacity for myocardial regeneration. Circ. J. 2010, 74(1):188-194.
48. Senegaglia A.C., et al. Are purified or expanded cord blood-derived CD133+ cells better at improving cardiac function?. Exp. Biol. Med. (Maywood) 2010, 235(1):119-129.
49. Shelley W.C., et al. Changes in the frequency and in vivo vessel-forming ability of rhesus monkey circulating endothelial colony-forming cells across the lifespan (birth to aged). Pediatr. Res. 2012, 71(2):156-161.
50. Sieveking D.P., et al. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J. Am. Coll. Cardiol. 2008, 51(6):660-668.
51. Smith R.A., et al. Glycosaminoglycans as regulators of stem cell differentiation. Biochem. Soc. Trans. 2011, 39(1):383-387.
52. Tarte K., et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010, 115(8):1549-1553.
53. Thornton S.C., Mueller S.N., Levine E.M. Human endothelial cells: use of heparin in cloning and long-term serial cultivation. Science 1983, 222(4624):623-625.
54. Vanneaux V., et al. In vitro and in vivo analysis of endothelial progenitor cells from cryopreserved umbilical cord blood: are we ready for clinical application?. Cell Transplant. 2010, 19(9):1143-1155.
55. Yamauchi H., et al. New agents for the treatment of infarcted myocardium. Faseb J. 2000, 14(14):2133-2134.
56. Yayon A., et al. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991, 64(4):841-848.
57. Yoder M.C., et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007, 109(5):1801-1809.
58. Zhao W., et al. Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharides. Biosci. Rep. 2012, 32(1):71-81.